PRVB - Provention Bio GAAP EPS of -$0.46 beats by $0.04 revenue of $0.75M beats by $0.05M
- Provention Bio press release ( NASDAQ: PRVB ): Q2 GAAP EPS of -$0.46 beats by $0.04 .
- Revenue of $0.75M beats by $0.05M .
- The company expects its cash-based operating expenses to be in the range of $27.0M to $31.0M for the third quarter of 2022.
-
Based on the company's current business plans, management believes that its cash, cash equivalents and marketable securities on hand as of June 30, 2022, together with the approximately $57.2 million in net proceeds from the July 2022 Private Placement, will be sufficient to fund the company's operating requirements for at least the next 12 months from the issuance of the company's financial statements for the quarter ended June 30, 2022.
For further details see:
Provention Bio GAAP EPS of -$0.46 beats by $0.04, revenue of $0.75M beats by $0.05M